FOCIS® 2017
CHICAGO  JUNE 14-17
Precision in Immunology

SCIENTIFIC PROGRAM
Thank you to the FOCIS 2017 Travel Award Supporters:
Dear Colleagues,

Welcome to the 17th annual meeting of the Federation of Clinical Immunology Societies, FOCIS 2017. I am particularly excited about this year’s meeting. The scientific program reflects the core tenets of FOCIS by bridging the gap between basic and clinical immunology and discussing novel translational therapies.

We value the participation of each of you who have touched FOCIS in one way or another over the past 17 years, and we hope that you will join us as we move into the future. FOCIS introduced individual membership in 2012, and I invite you to join FOCIS and collaborate with us to promote education, research and patient care around the theme of translational immunology. Memberships run on a calendar year basis and are available at the conference. At FOCIS 2017, membership also gains you exclusive access to a Members-only Lounge complete with a complimentary espresso bar as well as a festive Members-only Reception at Kitty O’Sheas on Thursday, June 16.

Please join me in extending my most heartfelt thanks to the members of the FOCIS 2017 Scientific Program Committee for their time, energy and expertise. I hope you enjoy the fruits of their labor – FOCIS 2017. Welcome to Chicago!

Sincerely,

Jeffrey Bluestone, PhD, FOCIS President
University of California, San Francisco

FOCIS 2017 SUPPORTERS

ACKNOWLEDGEMENTS:
FOCIS gratefully acknowledges the support that allows FOCIS to fulfill its mission to foster interdisciplinary approaches to both understand and treat immune-based diseases, and ultimately to improve human health through immunology.

EXHIBITORS:
Arcus Biosciences
Beckman Coulter
BioLegend
Cellular Technology Limited
Immudex
iRepertoire, Inc.
JPT Peptide Technologies
Merck
Myriad RBM
Nanostring Technologies
Science Immunology

MOBILE APP
Use your mobile phone/tablet to view the program, make a personal schedule, view the exhibits and much more!
EVALUATIONS:
Daily online evaluations are available through the mobile app. Delegates will also receive an email reminder and link to the evaluations daily during the meeting. Delegates are asked to complete an evaluation for each session attended. If you are eligible for a travel award, you must complete the evaluations before receiving a reimbursement.

CME CERTIFICATES AND CERTIFICATES OF ATTENDANCE:
In the past, FOCIS has made it possible for meeting participants to obtain CME credit for attending the annual meeting. In order to enable all those involved in the research and treatment of immune-mediated diseases to participate in the exchange of ideas that contribute to the forward motion of the field, FOCIS will not offer CME credit for FOCIS 2017. Certificates of attendance will be available upon request.

EXHIBIT HALL HOURS:
Located in Stevens Salon A (lower level)
Wednesday, June 14 4:00 pm – 7:45 pm
Thursday, June 15 8:00 am – 7:00 pm
Friday, June 16 8:00 am – 7:30 pm

POSTER HALL HOURS:
Located in Stevens Salon A (lower level)
Wednesday, June 14 4:00 pm – 7:45 pm
Thursday, June 15 8:00 am – 7:00 pm
Friday, June 16 8:00 am – 7:30 pm

POSTER SET-UP AND TAKE-DOWN HOURS:
Wednesday, June 14 Set-up: 12:00 pm – 12:45 pm
Take-down: 7:45 pm – 8:00 pm
Thursday, June 15 Set-up: 7:00 am – 8:00 am
Take-down: 7:00 pm – 7:15 pm
Friday, June 16 Set-up: 7:00 am – 8:00 am
Take-down: 7:30 pm – 7:45 pm

REGISTRATION AND SPEAKER CHECK-IN HOURS:
Located in Normandie Lounge (2nd Floor)
Tuesday, June 13 1:00 pm – 5:00 pm
*FOCISed Course Registration Located on 3rd Floor
(7:00 am – 12:00 pm) - Williford Foyer
Wednesday, June 14 7:00 am – 5:00 pm
Thursday, June 15 7:00 am – 5:00 pm
Friday, June 16 7:00 am – 5:00 pm

SPEAKERS:
Speakers are asked to report to the speaker check-in area located at the Registration Desk (Normandie Lounge, 2nd Floor) of the Hilton Chicago Hotel at least 24 hours prior to the start of their session.

PHOTOGRAPHY POLICY:
Please refrain from photography in the sessions and poster hall.

RELEASE:
Registration and attendance at, or participation in, FOCIS meetings and other activities constitutes an agreement by the registrant to FOCIS’ use and distribution (both now and in the future) of the registrant or attendee’s image or voice in photographs, videotapes, electronic reproductions and audio tapes of such events and activities.
You're Invited to join FOCIS

Member Perks at FOCIS 2017

Grow your network
Member Lounge
Normandie Lounge
open daily during FOCIS 2017

Work, relax and mingle
Member Reception
Kitty O'Sheas
Thursday, June 15, 7:00 - 8:00 p.m.

Join FOCIS at the Registration Desk

Advanced Course in Basic & Clinical Immunology
February 18-21, 2018
The Scott Resort & Spa
Scottsdale, AZ
Tuesday, June 13

7:00 am – 12:00 pm
FOCISed Course Registration Open
Williford ABC Foyer (3rd Floor)

8:00 am – 5:15 pm
Basic Immunology in Medicine: Update 2017
(separate registration required)
Williford A (3rd Floor)

7:30 am – 4:30 pm
Computational Immunology Course
(separate registration required)
Williford C (3rd Floor)

1:00 pm – 5:00 pm
Registration Desk Open
Normandie Lounge (2nd Floor)

Wednesday, June 14

7:00 am – 5:00 pm
Registration Desk Open
Normandie Lounge (2nd Floor)

7:30 am – 5:00 pm
Cancer Immunity and Immunotherapy Course
(separate registration required)
Stevens Salon A-5 (lower level)

Member Society Symposia
(included in FOCIS 2017 registration)

8:00 am – 10:00 am
IL-1b in Health and Disease
Organized by the Canadian Society for Immunology (CSI)
Stevens Salon A-1 (lower level)

8:00 am
Overview on IL-1beta in Health and Autoinflammatory Disease
Kelly Brown, PhD, University of British Columbia

8:30 am
Clinical Phenotypes of Autoinflammatory Diseases
Rosie Scuccimarra, MD, McGill University

9:00 am
Regulation of Inflammation During Ontogeny
Pascal Lavoie, MD, PhD, University of British Columbia

9:30 am
Inflammasomes and Cell Death Pathways in Inflammatory Diseases and Cancer
Maya Saleh, PhD, McGill University

8:00 am – 12:00 pm
Cytokines and Interferons in Basic and Clinical Immunology: Reports from the ICIS
Organized by the International Cytokine and Interferon Society
Stevens Salon A-2 (lower level)
LIFECODES®
Enhanced LSA Class I and II Single Antigen Assays

We are excited to bring you the next generation in LIFECODES® HLA Class I & II Single Antigen testing!

FEATURES:
• Expanded antigen panel
• Refined calculation for positive/negative assignments
• Standardization of antigen density from lot to lot, and reagents across product lines
• 20:40 Serum to Beads ratio option
• A new blocker added to LSA II to reduce background reactivity

CONTACT YOUR IMMUCOR REPRESENTATIVE TODAY AND SCHEDULE AN EVALUATION.

immucor.com  855.IMMUCOR
Wednesday, June 14 (continued)

8:00 am – 12:00 pm
Translational Immunology at the NIH:
A Look at the Future Organized by the National Institutes of Health Immunology Interest Group (IIIG)
Stevens Salon C-2 (lower level)

8:00 am  The Coming of Age of JAK Inhibitors: From Targets to Treatments
Massimo Gadina, PhD, National Institutes of Health

8:30 am  An Immunodeficiency and Autoimmunity Disease Caused by Mutations in BACH2
Behdad Afzali, PhD, National Institutes of Health

9:00 am  Altered Dendritic Cell Function in Autoimmune Diabetes
Kristin Tarbell, PhD, National Institutes of Health

9:30 am  IL-18 at the Intersection of Auto- and Hyper-inflammation
Scott Canna, MD, National Institutes of Health

10:00 am  Coffee Break

10:15 am  Developing Standard Operating Procedures for SLE Target Tissue Processing and Analysis Across the Network
Celine Berthier PhD, University of Michigan

10:30 am  Patient Selection and Characteristics for SLE Phase 1
Jill Buyon MD, New York University

10:45 am  Insights from Comparison of the Renal and Skin Single Cell Transcriptome in SLE
Jill Buyon MD, New York University
Tom Tuschi, PhD, Rockefeller University

11:15 am  Cellular and Molecular Heterogeneity in Lupus Nephritis
Arnon Arazi, PhD, Broad Institute

11:45 am  Integrating Immune Insights Learned from Phase 1 and Anticipating Technical and Clinical Approaches for SLE AMP Phase 2
Deepak Rao, MD, PhD, Brigham and Women’s Hospital

8:00 am – 12:00 pm
Exosomes and Cross-presentation in Transplantation
Organized by the American Society for Transplantation, The Transplantation Society, and American Society for Histocompatibility and Immunogenetics
Stevens Salon C-4 (lower level)

8:00 am  Apoptosis in Exosome Generation
Marie Josée Herbert, PhD, University of Montreal

8:30 am  Transfer of Donor Exosomes: A Novel System to Promote Allo-reactivity in Transplantation
Adrian Morelli, MD, PhD, University of Pittsburgh

9:00 am  Tissue Specific Exosomes as Biomarkers
Prashanth Vallabhap, MD, University of Pennsylvania

9:30 am  Exosomal Profiling in Lung Transplantation
Thalachallour Mohanakumar, PhD, St. Joseph’s Hospital and Medical Center

The AMP RA/Lupus Network: Deconstructing RA and SLE Through Single Cell Analysis
Organized by the Accelerating Medicines Partnership (AMP)
Stevens Salon C-3 (lower level)

8:00 am  Approach and Goals of the RA/Lupus Network
Michael Brenner, MD, Brigham and Women’s Hospital

8:15 am  Developing Standard Operating Procedures for RA Target Tissue Processing and Analysis Across the Network
Deepak Rao, MD, PhD, Brigham and Women’s Hospital

8:30 am  Patient Selection for RA Phase 1 and Synovial Biopsy Program
Jennifer Anolik, MD, PhD, University of Rochester

8:50 am  CyTOF as an Approach for Deconvolution of Immune Cell Infiltrates in the Synovium and Blood
Jim Lederer, PhD, Brigham and Women’s Hospital

9:10 am  Insights into RA Pathogenesis from Single Cell Transcriptomics of Synovial Tissue
Kamil Slowikowski, Harvard University

9:40 am  Integrating Immune Insights Learned from Phase 1 and Anticipating Technical and Clinical Approaches for RA AMP Phase 2
Michael Brenner, MD, Brigham and Women’s Hospital

10:00 am  Coffee Break

10:15 am  Developing Standard Operating Procedures for SLE Target Tissue Processing and Analysis Across the Network
Celine Berthier PhD, University of Michigan

10:30 am  Patient Selection and Characteristics for SLE Phase 1
Jill Buyon MD, New York University

10:45 am  Insights from Comparison of the Renal and Skin Single Cell Transcriptome in SLE
Jill Buyon MD, New York University
Tom Tuschi, PhD, Rockefeller University

11:15 am  Cellular and Molecular Heterogeneity in Lupus Nephritis
Arnon Arazi, PhD, Broad Institute

11:45 am  Integrating Immune Insights Learned from Phase 1 and Anticipating Technical and Clinical Approaches for SLE AMP Phase 2
Deepak Rao, MD, PhD, Brigham and Women’s Hospital
The Lupus Research Alliance unites the global lupus community in bold determination to free the world of lupus through the power of science.

We will transform the lives of people affected by lupus as we welcome and embrace a new scientific era, pioneer innovation, push the frontiers of knowledge, enlist diverse new scientific talent, and lead the drive to new treatments, prevention and cure.
Wednesday, June 14 (continued)

12:00 pm – 2:00 pm
(Invitation Only)
Boulevard AB (2nd Floor)

12:45 pm – 4:45 pm
Type I Interferon Pathogenic Mediator and Therapeutic Target
Organized by the American College of Rheumatology (ACR)
Stevens Salon A-1 (lower level)

12:45 pm
Plasmacytoid Dendritic Cells – Regulation and Role in Autoimmune Disease Pathogenesis
Boris V. Reizis, PhD, Columbia University

1:30 pm
Immune Dysfunction and Tissue Pathology Mediated by Type I Interferon: Studies in Murine Lupus Models
Dwight H. Kono, MD, The Scripps Research Institute

2:15 pm
Type I Interferon in the Immunopathogenesis of Chronic Virus Infection
David G. Brooks, PhD, University of California, Los Angeles

2:50 pm
Coffee Break

3:00 pm
Type I Interferons in Inflammatory Myopathies
Steven A. Greenberg, MD, Brigham and Women’s Hospital

3:45 pm
Mary K. Crow, MD, Hospital for Special Surgery

3:30 pm
Coffee Break

3:30 pm
Type I Interferons in Inflammatory Myopathies
Steven A. Greenberg, MD, Brigham and Women’s Hospital

4:15 pm
Opportunities for Therapeutic Targeting of Type I Interferon
Mary K. Crow, MD, Hospital for Special Surgery

4:20 pm
The Role for PD-1 in Experimental Autoimmune Uveitis
Lynn Gordon, MD, PhD, University of California, Los Angeles

4:45 pm
Panel Discussion

12:45 pm – 5:00 pm
Update on Animal Models and Pre-clinical Targets for Immune Mediated Uveitis
Organized by the American Uveitis Society (AUS)
Stevens Salon A-2 (lower level)

12:45 pm
Introduction and Welcome
Barbara Detrick, PhD, Johns Hopkins University

1:20 pm
Biomarkers of Transplant Injury
Elaine Reed, PhD, University of California, Los Angeles

2:00 pm
Gene Expression Profiling of the Tumor Microenvironment as a Biomarker for Anti-tumor Immunity
Thomas F. Gajewski, MD, PhD, University of Chicago

2:40 pm
Antibodies and Graft Injury
Chris Wiebe, MD, University of Manitoba

3:20 pm
Coffee Break

3:20 pm
Dendritic Cell Based Immunotherapy in Cancer
Willie Hildebrand, PhD, University of Oklahoma

4:00 pm
Strategies for Therapy in SLE and RA Based on Laboratory Evaluation of the Interferons
Timothy B. Niewold, MD, Mayo Clinic

2:25 pm
Multimodal Non-invasive for Quantitative Assessment of Inflammation in Animal Models of Uveitis
Kathryn Pepple, MD, PhD, University of Washington

2:50 pm
Coffee Break

3:20 pm
Chasing Immune Cells in the Eye: From Mouse to Man
Colin Chu, PhD, University of Bristol

3:45 pm
Therapeutic Targeting of Pathogenic Lymphocytes that Mediate Uveitis
Charles Egwuagu, PhD, MPH, National Institutes of Health

4:10 pm
Predicting the Future of Uveitis Treatment: Top Targets and Therapies on the Horizon
Phoebe Lin, MD, PhD, Casey Eye Institute

4:45 pm
Panel Discussion

12:45 pm – 4:45 pm
Molecular Signatures: Providing Clues for Management and Therapy in Transplantation, Autoimmune Disease and Cancer
Organized by the Association of Medical Laboratory Immunologists (AMLI) and the American Society for Histocompatibility and Immunogenetics (ASHI)
Stevens Salon C-1 (lower level)

12:45 pm
Introduction
Barbara Detrick, PhD, Johns Hopkins University

12:55 pm
Biomarkers of Transplant Injury
Elaine Reed, PhD, University of California, Los Angeles

1:30 pm
Gene Expression Profiling of the Tumor Microenvironment as a Biomarker for Anti-tumor Immunity
Thomas F. Gajewski, MD, PhD, University of Chicago

2:00 pm
New Molecular Markers for Type 1 Diabetes
Martin J. Hessner, PhD, Medical College of Wisconsin

2:40 pm
Antibodies and Graft Injury
Chris Wiebe, MD, University of Manitoba

3:15 pm
Coffee Break

3:30 pm
Dendritic Cell Based Immunotherapy in Cancer
Willie Hildebrand, PhD, University of Oklahoma

4:05 pm
Strategies for Therapy in SLE and RA Based on Laboratory Evaluation of the Interferons
Timothy B. Niewold, MD, Mayo Clinic

12:45pm – 3:30 pm
Immune Cells as Therapies
Organized by the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)
Stevens Salon C-2 (lower level)

12:45 pm
Introduction
Barbara Detrick, PhD, Johns Hopkins University

12:55 pm
Biomarkers of Transplant Injury
Elaine Reed, PhD, University of California, Los Angeles

1:30 pm
Gene Expression Profiling of the Tumor Microenvironment as a Biomarker for Anti-tumor Immunity
Thomas F. Gajewski, MD, PhD, University of Chicago

2:00 pm
New Molecular Markers for Type 1 Diabetes
Martin J. Hessner, PhD, Medical College of Wisconsin

2:40 pm
Antibodies and Graft Injury
Chris Wiebe, MD, University of Manitoba

3:15 pm
Coffee Break

3:30 pm
Dendritic Cell Based Immunotherapy in Cancer
Willie Hildebrand, PhD, University of Oklahoma

4:05 pm
Strategies for Therapy in SLE and RA Based on Laboratory Evaluation of the Interferons
Timothy B. Niewold, MD, Mayo Clinic

12:45pm – 3:30 pm
Immune Cells as Therapies
Organized by the American Society for Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)
Stevens Salon C-2 (lower level)
Caladrius Biosciences Salutes the Clinicians and Researchers Bringing Immunotherapies to Patients in Need

We thank you for your hard work healing patients and advancing medicine.

Your dedication not only saves lives but advances the field by bringing innovation and new therapies through clinical development directly to the patients who need them.

At Caladrius, we are advancing CLBS03, our unique product candidate using T regulatory cells to treat the underlying cause of type 1 diabetes.

CLBS03 is currently being investigated in a landmark Phase 2 clinical trial – The Sanford Project: T-Rex Study – to evaluate its ability to preserve beta cell function in patients with recent onset type 1 diabetes.

Learn more at www.caladrius.com
### Wednesday, June 14 (continued)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 pm</td>
<td>Introduction</td>
<td>Marcela Maus, MD, PhD, Massachusetts General Hospital</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Update on CD19 CAR T Cells in B Cell Malignancies</td>
<td>Stephen Grupp, MD, PhD, Children’s Hospital of Philadelphia</td>
</tr>
<tr>
<td>1:30 pm</td>
<td>CAR T Cells in Non-B Cell Hematologic Malignancies</td>
<td>Marcela Maus, MD, PhD, Massachusetts General Hospital</td>
</tr>
<tr>
<td>2:00 pm</td>
<td>CAR T Cells in Solid Tumors</td>
<td>Prasad Adusumilli, MD, Memorial Sloan Kettering Cancer</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Managing Complications of CAR T Cell Therapies</td>
<td>Sarah Nikiforow, MD, PhD, Dana Farber Cancer Institute</td>
</tr>
<tr>
<td>3:00 pm</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

#### 12:45pm – 4:45 pm Insights into the Immunology of Chronic Fatigue Syndrome
*Organized by the Division of Allergy, Immunology & Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 pm</td>
<td>Welcome and Objectives</td>
<td>Joseph Breen, PhD, National Institutes of Health and Vicky Whittemore, PhD, National Institute of Neurological Disorders and Stroke</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>The Public Health Problem of ME/CFS</td>
<td>Elizabeth Unger, MD, Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>1:15 pm</td>
<td>Evidence of T Cell Activity in ME/CFS</td>
<td>Mark Davis, PhD, Stanford University</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Immunological Characterization of ME/CFS Cases and Controls from the UK ME/CFS Biobank</td>
<td>Eleanor Riley, PhD, University of London</td>
</tr>
<tr>
<td>2:35 pm</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>2:55 pm</td>
<td>Pathobiology of ME/CFS</td>
<td>Ian Lipkin, MD, Columbia University</td>
</tr>
<tr>
<td>3:35 pm</td>
<td>Circulating Cytokine Signatures Associated with ME/CFS Severity and Duration</td>
<td>Jose Montoya, MD, Stanford University</td>
</tr>
<tr>
<td>4:15 pm</td>
<td>Question/Answer Forum</td>
<td></td>
</tr>
</tbody>
</table>

#### 6:15 pm – 7:45 pm

*Opening Reception*

**Stevens Salon A** *(lower level)*

Network with attendees while visiting exhibits and posters with authors present. Complimentary light hors d’oeuvres and wine served.

### Thursday, June 15

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>Registration Desk Open</td>
<td>Normandie Lounge <em>(2nd Floor)</em></td>
</tr>
<tr>
<td>8:00 am</td>
<td>Posters Available for Viewing (authors optional)</td>
<td>Stevens Salon A <em>(lower level)</em></td>
</tr>
<tr>
<td>8:00 am</td>
<td>T Cell Subsets and Their Responses to Pathogens and Autoantigens</td>
<td>Grand Ballroom <em>(2nd Floor)</em></td>
</tr>
<tr>
<td>9:00 am</td>
<td>Is Narcolepsy an Autoimmune Disease?</td>
<td></td>
</tr>
</tbody>
</table>

#### 8:00 am

**Anergy Induction in Self-reactive CD4 T-Cells Generates FoxP3+ Treg Progenitors**

Daniel Mueller, MD, University of Minnesota

#### 8:30 am

**T Cell and Innate Subsets in Chronic Immune Mediated Disease**

Vijay Kuchroo, PhD, Brigham and Women’s Hospital

#### 9:00 am

**Is Narcolepsy an Autoimmune Disease?**

Federica Sallusto, MD, Institute for Research in Biomedicine  

### 10:00 am – 11:30 am

#### 10:00 am

**Understanding the Crosstalk Between Lipid Metabolism and Innate Immunity**

Steven Bensinger, MD, PhD, University of California, Los Angeles

#### 10:30 am

**Fueling the Immune Response**

Chair: Angela Colmone, PhD, Science Immunology

#### 11:00 am

**Immunometabolism of Regulatory T Cells**

Laurence Turka, MD, Harvard University

#### 11:30 am – 1:00 pm

**Lunch Break**

Delegates on their own for lunch

#### 11:45 am – 1:00 pm

**Biolegend Industry Workshop**

**Stevens Salon A-1** *(lower level)*

**Beckman Coulter Industry Workshop**

**Stevens Salon A-5** *(lower level)*
HARNESS THE POWER OF ADVANCED SENSITIVITY AND RESOLUTION.

The CytoFLEX Flow Cytometer has the dynamic range to see dim and bright populations in the same sample. And with 15 parameters, including 13 channels for fluorescent detection, heterogeneous populations can be defined with exquisite clarity.

Learn more at goo.gl/Ew8KYw
Thursday, June 15 (continued)

11:45 am – 1:00 pm
Lupus Insight Prize Award
Presented by the Lupus Research Alliance
Boulevard AB (2nd Floor)

1:00 pm – 2:45 pm
Strategies for Antigen Specific Tolerance
Stevens Salon A-1 (lower level)
Chair: Daniel Rotrosen, MD, National Institutes of Health

1:00 pm Next Generation Regulatory T Cell Therapy
Megan Levings, PhD, University of British Columbia

1:25 pm Abstract Presentation: Transient Antibody Targeting of CD45RC Induces Transplantation Tolerance and Potent Donor Antigen-specific Regulatory Cells (Poster # T.83)
Ignacio Anegon, MD, Nantes University

1:40 pm Antigen-based Immunotherapy for Type 1 Diabetes
Mark Peakman, PhD, King’s College London

2:05 pm Abstract Presentation: The Effects of Oral Insulin in Individuals at Risk of Type 1 Diabetes: A TrialNet Randomized Clinical Trial (Poster # T.68)
Carla Greenbaum, MD, Benaroya Research Institute

2:20 pm Antigen-specific Tolerance in Allergic Disease
Mark Larche, PhD, McMaster University

1:00 pm – 2:45 pm
Macrophage Subsets in Normal and Abnormal Human Immune Function
Stevens Salon A-2 (lower level)
Chair: Tim Niewold, MD, Mayo Clinic

1:00 pm Macrophages in Tissue Repair, Regeneration, and Fibrosis
Thomas A. Wynn, PhD, National Institute of Allergy and Infectious Diseases

1:25 pm Abstract Presentation: Hematoma-infiltrating Macrophages Transition from Inflammatory to Reparative Programs in Intracerebral Hemorrhage Patients (Poster # T.58)
Michael Askenase, PhD, Yale University

1:40 pm Modulation of Innate Immune Receptor Outcomes in Human Disease
Clara Abraham, MD, Yale University

2:05 pm Abstract Presentation: Cross-talk Between MS Disease-relevant B Cell Subsets and Microglia/macrophage: Implication in MS Disease Progression (Poster # T.4)
Hanane Touil, PhD, McGill University

2:20 pm Epigenetics of Tissue Resident Macrophages in Health and Disease
Christopher Glass, MD, PhD, University of California, San Diego

1:00 pm Microbiota and Cancer
Laurence Zitvogel, MD, PhD, Institut Gustave Roussy

1:25 pm Abstract Presentation: A Human Gut Commensal as a Cross-reactive Trigger of Autoantigen-specific CD4+ Memory T Cells in Antiphospholipid Syndrome (Poster # T.28)
Carina Dehner, MD, Yale University

1:40 pm Influence of Microbial Metabolites on Disease Pathogenesis
Thaddeus Stappenbeck, MD, PhD, Washington University

2:05 pm Abstract Presentation: Bacterial Dysbiosis Associates with Functional Intraepithelial Lymphocyte Changes in Inflammatory Bowel Disease and Spondyloarthritis (Poster # T.29)
Neha Ohri, MD, MS, Mount Sinai Hospital

2:20 pm Regulation of Allergic Responses to Food by Commensal Bacteria
Cathryn Nagler, PhD, University of Chicago

2:45 pm – 3:00 pm
Networking Break
Stevens Salon A (lower level)

3:00 pm – 4:45 pm
Oral Abstract Sessions
Environmental Effects on the Immune System
Stevens Salon A-1 (lower level)
Chair: James Lord, MD, PhD, Benaroya Research Institute

3:00 pm Metabolite Regulation of Human T Cell Immunity (Poster # T.45)
Maria Matias, MSc, University of Montpellier

3:13 pm Molecular and Cellular Mechanisms for B Cell Defects in Elderly and Obese Subjects (Poster # T.49)
Bonnie Blomberg, PhD, University of Miami, James Lord, MD, PhD, Benaroya Research Institute

3:26 pm Aging of Adaptive Immunity Driven by Chronic Antigen Exposition has a Major Impact on the Course of Regenerative Processes Which are Overlooked in Our Commonly Used Mouse Models (Poster # T.50)
Hans-Dieter Volk, Charité University

3:39 pm Comparison of IgA+ Plasma Cells in the Intestinal Mucosa Compartment Versus the Periphery in a Healthy Kenyan Cohort (Poster # T.46)
Tian Sun, University of Toronto

3:52 pm Autophagic Memory in Stress Experienced Human T Cells (Poster # T.27)
Pavanish Kumar, PhD, SingHealth Translational Immunology and Inflammation Centre
AT BRISTOL-MYERS SQUIBB, WE ARE WORKING TOGETHER FOR PATIENTS

Our mission is clear — we discover, develop and deliver transformational medicines that help people prevail over serious diseases.

Our sense of urgency is real — we work every day to push the boundaries of scientific discovery and to make a meaningful difference in the lives of patients.

It’s what we do. It’s why we do it.

Bristol-Myers Squibb

www.bms.com
Thursday, June 15 (continued)

3:00 pm – 4:45 pm
Therapeutic Immunomodulation
Stevens Salon A-5 (lower level)
Chairs: Amit Bar-Or, MD, University of Pennsylvania

3:00 pm  Modulating IL-6/STAT3 Signaling Pathway for Multiple Sclerosis Therapy (Poster # T.4)
Saba Aqel, BS, Ohio State University

3:15 pm  Interleukin-34, a New and Potent Regulatory Cytokine Involved in Treg Function and Transplant Tolerance (Poster # T.88)
Carole Guillonneau, PhD, Nantes University

3:30 pm  Selective Expansion of PD-1+TIGIT+ CD4 T Cells Following Depletion of CD2high Cells with Alefacept in Recent Onset T1D (Poster # T.74)
Duangchan Suwannasaen, PhD, Benaroya Research Institute

3:45 pm  Perturbations within the T Cell Immunome in Polyarticular Juvenile Idiopathic Arthritis Patients Who Relapse Upon Withdrawal of Biologic Therapy (Poster # T.26)
Jing Yao Leong, PhD, Singapore Health Services Pte Ltd

4:00 pm  Complement C1q Limits Osteoarthritis Pathology by Regulating Macrophage Activation (Poster # T.25)
Bryan Cannon, MSc, Stanford University

4:15 pm  Initial Data from a Phase 2 Multiple Ascending Dose Clinical Trial of SEL-212 Indicates That the Addition of Tolerogenic Nanoparticles to Pegylated Uricase Enables Sustained Control of Serum Uric Acid in Symptomatic Gout Patients (Poster # T.65)
Earl Sands, MD, Selecta Biosciences

4:30 pm  T Cell Immunotherapies Trigger Innate Immunity and Aseptic Inflammation Leading to Potent Anti-tumor and Off-targets Effects (Poster # T.53)
Daniel Hirschhorn Cymerman, PhD, Memorial Sloan Kettering Cancer Center

3:00 pm – 5:00 pm
Principles of Flow Cytometry for Immune Monitoring Course
Boulevard AB (2nd Floor)
Co-Sponsored by NIAID’s Development of Sample Sparking Assays Program

Panel Discussion: Standard Guidelines for Flow Cytometry Gating
Panelists: Janet Staats, BS, Duke University
Anagha Divekar, PhD, Biolegend, Inc.
J. Philip McCoy, PhD, National Institutes of Health
Holden Maecker, PhD, Stanford University

5:00 pm – 5:05 pm
Presentation of the FCE Fusion Award
Grand Ballroom (2nd Floor)
Megan Levings, PhD, University of British Columbia
Creating a world free from immune diseases.
That’s our vision.

At Janssen, we like to dream big. And our hope for immune and inflammatory diseases is no exception.

Through science and collaboration, we look to transform how diseases like rheumatoid arthritis, Crohn’s disease and plaque psoriasis are treated today—and prevented tomorrow.

We dream of a future free of the pain and challenges for the approximately one in 10 people worldwide living with these diseases. We are relentless in our pursuit to advance science and deliver breakthrough medicines to make a difference in people’s lives.

But bringing forward new solutions isn’t enough. We want to shorten the journey from diagnosis to treatment. And through our education and access programs, we’re here to help forge that path.

We are Janssen. We collaborate with the world for the health of everyone in it.

Learn more at www.janssen.com
Thursday, June 15 (continued)

5:05 pm – 5:10 pm
Presentation of the C. Garrison Fathman Fellows Fund
Trainee Travel Award
Grand Ballroom (2nd Floor)
Megan Levings, PhD, University of British Columbia

5:00 pm – 5:55 pm
Keynote Address: Dissecting the Tumor Ecosystem with
Single Cell Genomics
Aviv Regev, PhD, Broad Institute
Grand Ballroom (2nd Floor)
Chair: Maria-Grazia Roncarolo, MD, Stanford University

5:55 pm – 7:00 pm
Exhibits and Poster Reception
Stevens Salon A (lower level)
Network with attendees while visiting exhibits and posters
with authors present. Complimentary light hors d'oeuvres
and wine served.

7:00 pm – 8:00 pm
FOCIS Member Reception (FOCIS members only)
Kitty O’Sheas (lobby level)
Join us for hors d’oeuvres, drinks and fun! Let FOCIS show
you how much we value you!
Not a member? Join now at the registration desk.

Friday, June 16

7:00 am – 5:00 pm
Registration Open
Normandie Lounge (2nd Floor)

7:30 am – 6:15 pm
Posters Available for Viewing
(authors optional)
Stevens Salon A (lower level)

8:00 am – 9:30 am
Cancer Immunotherapy: Have We Reached a Checkpoint
or the End?
Grand Ballroom (2nd Floor)
Chair: Arlene Sharpe, MD, PhD, Harvard University

8:00 am
Anti-PD-1 in Cancer Immunotherapy: State of the Art and What Lies Ahead
Suzanne Topalian, MD, Johns Hopkins University

8:30 am
Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities
James Allison, PhD, MD Anderson Cancer Center

9:00 am
Measuring the T-Cell Repertoire in Checkpoint Inhibitor-Induced Cancer Regression
Drew Pardoll, MD, PhD, Johns Hopkins University

9:30 am – 10:00 am
Networking Break
Stevens Salon A (lower level)

9:55 am – 10:00 am
Scientific Program Committee Awards Presentation
Grand Ballroom (2nd Floor)

10:00 pm – 11:30 pm
Genomics in Health and Disease
Exhibits and Poster Reception
Grand Ballroom (2nd Floor)
Chair: Ignacio Anegon, MD, Nantes University

10:00 am
Identification of New Syndromic Forms of Severe Combined Immune Deficiency
Luigi Notarangelo, MD, National Institutes of Health

10:30 am
Genomic Analyses of Primary Immunodeficiencies Yield Precision Medicine Treatments
Michael J. Lenardo, MD, National Institute of Allergy and Infectious Disease

11:00 am
Genetic and Genomic Approaches to Asthma Gene Discovery
Carole Ober, PhD, University of Chicago

11:30 am – 1:00 pm
Lunch Break
Delegates on their own for lunch

11:45 am – 1:00 pm
Lunch Programs
NIH Grant Applications: Common Pitfalls and Tips for Writing Successful Applications
Stevens Salon A-1 (lower level)

11:45 am
The Role of Batf3 DC in the Recruitment of Tumor-specific Effector T Cells
Stefani Spranger, PhD, Massachusetts Institute of Technology

12:00 pm
Human CD8+CD45RClowFoxp3+ Tregs with High Tolerogenic Activity in Humanized Mice and Defined Alloantigen Specificity
Carole Guillonneau, PhD, Université de Nantes

12:15 pm
IL-33 and ST2: Therapeutic Targets and Emerging Biomarkers in Solid Organ and Bone Marrow Transplantation
Heth Turnquist, PhD, University of Pittsburgh
Save time, money, and reagents with Veri-Cells™, our new lyophilized human control cells for flow cytometry, validated to provide consistent assay-to-assay results.

Learn more at: biolegend.com/veri-cells

- Exceptional long term stability
- Scatter profile similar to fresh samples
- Validated to detect 160+ markers
- Monitor data quality and reproducibility in multi-center and longitudinal studies
1:00 pm  Massively Multiplexed Single Cell Analysis in Human Immune Homeostasis  
Seth Bendall, PhD, Stanford University

1:00 pm – 2:45 pm  
Alarmins as Immune Targets  
Stevens Salon A-1 (lower level)  
Chair: Megan Sykes, MD, Columbia University

1:00 pm  Environmental Effects on Immunity and Asthma and Atopy Risk: Lessons from Amish and Hutterite Farm Children  
Anne Sperling, PhD, University of Chicago

1:25 pm  Abstract Presentation: Expression and Regulation of Amphiregulin in Human Regulatory T Cells (Poster # F.20)  
Avery Lam, PhD, University of British Columbia

1:40 pm  Neutrophils as Players and Therapeutic Targets in Systemic Autoimmunity  
Mariana Kaplan, MD, National Institute of Arthritis and Musculoskeletal and Skin Diseases

2:05 pm  Abstract Presentation: Increased Levels of Sputum Antibodies to a Subset of Citrullinated Peptide Antigens Correlate with Sputum Neutrophil Extracellular Trap Levels in Subjects At-risk for Future RA (Poster # F.11)  
Kristen Demoruelle, MD, University of Colorado

2:20 pm  Coincident Detection Mechanism in Tissue Repair Responses  
Carla Rothlin, PhD, Yale University

1:00 pm – 2:45 pm  
Genetic & Epigenetic Control of Immune Responses  
Stevens Salon A-2 (lower level)  
Chair: David A. Hafler, MD, Yale University

1:00 pm  ATAC-ing Gene Regulatory Variation in the Blood  
William Greenleaf, PhD, Stanford University

1:25 pm  Abstract Presentation: Exhaustion-associated de Novo DNA Methylation Restrains PD-1 Blockade-Mediated T-Cell Rejuvenation (Poster # F.68)  
Hazem Ghoneim, PhD, St. Jude Children’s Research Hospital

1:40 pm  Drivers and Targets of Immunity in Humans  
Nir Hacohen, PhD, Harvard University

2:05 pm  Abstract Presentation: Rapid Functional Characterization of Rare and Common Immune Variants (Poster # F.30)  
Theodore Roth, University of California, San Francisco

2:20 pm  Engineering Human T Cell Circuitry  
Alex Marson, MD, PhD, University of California, San Francisco

1:00 pm – 2:45 pm  
Manipulating T Follicular Helper Cells and the Germinal Center  
Stevens Salon A-5 (lower level)  
Chair: Terri Laufer, MD, University of Pennsylvania

2:45 pm – 3:15 pm  
Networking Break  
Stevens Salon A (lower level)

3:15 pm – 5:15 pm  
Oral Abstract Sessions  
Precision Immunology  
Stevens Salon A-1 (lower level)  
Chair: William Robinson, MD, PhD, Stanford University

3:15 pm  The 10,000 Immunomes Project: A Data Resource of Human Immunology (Poster # F.27)  
Kelly Zalocusky, PhD, University of California, San Francisco

3:30 pm  Altered IL-2 and IL-7 Networks in T1D are Revealed Through Systems Analyses (Poster # F.77)  
S. Alice Long, PhD, Benaroya Research Institute

3:45 pm  Impact of Age, Sex and Genetics on Transcriptional Immune Responses to Bacterial, Viral and Fungal Challenges (Poster # F.35)  
Darragh Duffy, Institute Pasteur

4:00 pm  Low Natural Killer Cells Counts are Associated with Relapse After Imatinib Discontinuation in Chronic Myeloid Leukemia Patients: The IMMUNOSTIM Study (Poster # F.65)  
Antoine Toubert, MD, PhD, Hôpital Saint-Louis

4:15 pm  Distinct Single Cell Gene Expression Signatures of Monocyte Subsets Differentially Between TNF-alpha Inhibitor Treatment Response Groups in Rheumatoid Arthritis (Poster # F.9)  
Theresa Wampler Muskardin, MD, Mayo Clinic

4:30 pm  B Cell Subsets as Potential Biomarkers for Fingolimod Treatment in Multiple Sclerosis (Poster # F. TBD)  
Rui Li, MD, PhD, University of Pennsylvania

4:45 pm  Phosphatidylinositol 3-Kinase Delta Gain of Function (GOF) Mutations Cause Impaired B Cell Development and Function (Poster # F.60)  
Alisa Kane, PhD, Garvan Institute
Our strategy is based on three key principles: increasing innovation in R&D, seizing external growth opportunities and adapting the company’s model to future challenges and opportunities.

Sanofi has core strengths in healthcare, with 6 growth platforms: Immunology & Inflammation, emerging markets, vaccines, consumer healthcare, diabetes treatments, innovative products. Through the acquisition of Genzyme, Sanofi has reinforced its footprint in biotechnology and rare diseases. With approximately 110,000 employees in 100 countries, Sanofi and its partners act to protect health, enhance life and respond to the potential healthcare needs of the 7 billion people around the world.

Sanofi is proud to be a Gold Level Sponsor of the 2017 Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS).

For more information:
COR.11.02.007
Friday, June 16 (continued)

3:15 pm – 5:15 pm
The Forefront of Immune Regulation
Stevens Salon A-2 (lower level)
Chair: Megan Sykes, MD, Columbia University

3:15 pm
Suppression of Regulatory T Cells by Exosomes in Multiple Sclerosis (Poster # F.1)
Kimitoshi Kimura, MD, National Institute of Neuroscience

3:30 pm
Long Non-coding RNA and Methylome Profiles of Human Regulatory T Cells in Health and Disease (Poster # F.43)
Laura Passerini, PhD, San Raffaele Hospital

3:45 pm
Rebooting Autoimmunity after Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients by Newly-generated Regulatory T- and B-Cells (Poster # F.18)
Lucas Arruda, PharmD, MSc, University of São Paulo

4:00 pm
Distinct Alloimmune Stimulatory Profile of Monocyte-derived Dendritic Cells and CD40L-stimulated B Cells (Poster # F.80)
Linda Lee, PhD, University of California, San Francisco

4:15 pm
Enhancing Adoptive Cancer Immunotherapy with Vy2V∂2 T Cells through Pulse Zoledronate Stimulation (Poster # TBD)
Craig Morita, University of Iowa

4:30 pm
Modulation of Cbl-b in CD8+ T Cells Induces IFN-y Dependent Resistance Against Regulatory T Cell Immune Suppression (Poster # F.63)
Douglas Chung, Princess Margaret Hospital

5:00 pm
Permissive Epigenetic Marks at Regulatory T Cell Signature Genes in Fetal Naïve CD4+ T Cells Prime their Differentiation into Regulatory T Cells (Poster # F.70)
Melissa Ng, University of California, San Francisco

3:15 pm – 5:15 pm
Late Breaking Science
Stevens Salon A-5 (lower level)
Chair: Jordan Pober, MD, PhD, Yale University

3:15 pm
Identification of Unconventional Immunosuppressive CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity (Poster # F.64)
Roberta Zappasodi, Memorial Sloan Kettering Cancer Center

3:30 pm
Phenotypic and Functional Defects Underlie Ineffective Control of EBV in Patients with Distinct Primary Immunodeficiencies (Poster # F.56)
Emily Edwards, Garvin Institute of Medical Research

3:45 pm
The Epigenetic Landscape of T Cell Subsets in SLE Identifies Known and Potential Novel Drivers of the Autoimmune Response (Poster # F.8)
Jozsef Karman, Syros Pharmaceuticals

4:00 pm
Enhancer Connectome in Primary Human T Cells Reveals Target Genes of Autoimmune Disease-associated DNA Elements (Poster # F.24)
Ansuman Satpathy, Stanford University

4:15 pm
Enhancing Adoptive Cancer Immunotherapy with Vy2V∂2 T Cells through Pulse Zoledronate Stimulation (Poster # TBD)
Craig Morita, University of Iowa

4:30 pm
Modulation of Cbl-b in CD8+ T Cells Induces IFN-y Dependent Resistance Against Regulatory T Cell Immune Suppression (Poster # F.63)
Douglas Chung, Princess Margaret Hospital

5:00 pm
Permissive Epigenetic Marks at Regulatory T Cell Signature Genes in Fetal Naïve CD4+ T Cells Prime their Differentiation into Regulatory T Cells (Poster # F.70)
Melissa Ng, University of California, San Francisco
STRONG IDEAS NEED STRONG GLOBAL PARTNERS TO UNLEASH THEIR POTENTIAL.

GE Ventures provides small businesses, startups, and entrepreneurs with access to its global network of business units, partners and customers, and to its world-class training resources. All working to identify, scale and accelerate ideas that can advance industries and improve lives.

Learn more at geventures.com.
Saturday, June 17

8:00 am – 9:30 am
Cell Signaling
Grand Ballroom (2nd Floor)
Chair: Jordan Pober, MD, PhD, Yale University

8:00 am  Regulating Basal and Inducible TCR Signaling
          Arthur Weiss, MD, PhD, University of California, San Francisco

8:30 am  Cell Signaling Pathways Controlling HIV Infection and Latency
          Jonathan Karn, PhD, Case Western Reserve University

9:00 am  New Insights into B Cell Responses During Viral Infection
          Facundo Batista, PhD, Massachusetts General Hospital

9:30 am – 10:00 am
Networking Break
Grand Ballroom Foyer (2nd Floor)

10:00 am
Cellular Immune Therapies
Grand Ballroom (2nd Floor)
Chair: Maria-Grazia Roncarolo, PhD, Stanford University

10:00 am  Next-Gen T Cell-based Cancer Immunotherapies
          Nicholas Restifo, MD, National Institutes of Health

10:30 am  Regulatory Cellular Therapy in Renal Transplantation: The Phase IIb TWO Study
          Fadi Issa, MRCS, MSc, DPhil, University of Oxford

11:00 am  Virus T Cells Post-transplant: Broadening Applicability
          Catherine M. Bollard, MD, Children’s Research Institute

11:30 am – 1:00 pm
Lunch Break
Delegates on their own for lunch

1:00 pm – 2:45 pm
Tissue Resident Immune Cells: Targets for Immune Therapies
Williford A (3rd Floor)

1:00 pm  Molecular Programming of Tissue-resident Lymphocytes
          Laura K. Mackay, PhD, University of Melbourne

1:25 pm  Abstract Presentation: Chemotaxis of Terminally Differentiated CD8+ Cells (Temra) to the Sites of Sterile Infection: IL8-Receptors as an Answer?
          Iuliia Kotko, Charite University

1:40 pm  Resident Memory T Cells in Peripheral Tissues
          Thomas Kupper, MD, Brigham and Women’s Hospital

2:05 pm  Abstract Presentation: Tissue-reservoirs of Anti-viral T Cell Immunity in Persistent Human CMV Infection
          Michelle Miron, BA, Columbia University

2:20 pm  Human Circulating and Tissue-resident T Cells
          Donna Farber, PhD, Columbia University

1:00pm – 2:45 pm
Dissecting Single Cell and Tissue Heterogeneity at the Genome and Immunome Level
Williford B (3rd Floor)
Chair: Peter Linsley, PhD, Benaroya Research Institute

1:00 pm  A Defined Structure for the Immune System that Reflects Immune Surveillance and Mechanistic Processes
          Garry Nolan, PhD, Stanford University

1:25 pm  Abstract Presentation: Core Transcriptional and Functional Signatures Define Human Tissue-resident Memory T Cells in Lymphoid and Mucosal Sites
          Brahma Kumar, Columbia University

1:40 pm  Sequencing Antibody Repertoires to Decipher Pathogenic Mechanisms in Rheumatoid Arthritis
          William Robinson, MD, PhD, Stanford University

2:05 pm  Abstract Presentation: T Cell Library Assay Identified Functional ZnT8-specific Memory CD8+ T Cells in Patients with Type 1 Diabetes
          Hideki Ogura, Yale University

2:20 pm  Single Cell Analysis of Inflammatory Central Nervous Disease
          David Hafler, MD, Yale University

1:00pm – 2:45 pm
Next Generation Cytokine Modulation, Effector Tregs
Williford C (3rd Floor)
Chair: Brian Kotzin, MD

1:00 pm  Control of Effector Treg Maintenance and Function
          Daniel Campbell, PhD, Benaroya Research Institute

1:25 pm  Abstract Presentation: IL-17A Dampens Autoimmune Disease by Inhibiting the Expression of IL-17 Lineage Cytokines through a Negative Feedback Loop Involving IL-24
          Wai Po Chong, National Institutes of Health

1:40 pm  Impact of IL-27 on Infection-induced Inflammatory Processes
          Christopher A. Hunter, PhD, University of Pennsylvania

2:05 pm  Abstract Presentation: IL-2 Therapy Restores Regulatory T Cell Dysfunction Induced by Calcineurin Inhibitors
          Gavin Whitehouse, MD, King’s College London

2:20 pm  Genomic Views of Lymphocyte Activation and Differentiation
          John O’Shea, MD, National Institutes of Health
WORKING TO DELIVER THE PROMISE OF

CAR T CELL THERAPY

CAR T cell therapy is an investigational treatment approach in patients with relapsed or refractory B cell malignancies, such as ALL, CLL, or DLBCL.

Discover CAR T cell science, clinical development, and process at CARTCELLSCIENCE.com.

© 2017 Juno Therapeutics. All Rights Reserved.
Publish your research in Science Immunology

SUBMIT YOUR RESEARCH TODAY

Science Immunology, the newest member in the Science family of journals, provides original, peer-reviewed research articles that report critical advances in all areas of immunological research, including studies that provide insight into the human immune response in health and disease. Share your research with Science Immunology’s global readership and submit your manuscript today!

What will your discovery be?
Submit your manuscript today at
ScienceImmunology.org
Focused on innovation.

At Kadmon, we are dedicated to developing innovative therapies for autoimmune and fibrotic diseases, oncology and genetic diseases. We identify unique molecular targets to create new treatment paradigms for these unmet medical needs.

Our scientists have identified the importance of the Rho-associated Protein Kinase (ROCK) signaling pathway in regulating inflammatory responses. We are developing a portfolio of ROCK inhibitors that aim to resolve inflammation with a minimal effect on the rest of the immune response to potentially treat autoimmune and fibrotic diseases.

Learn more about our clinical pipeline at Kadmon.com.
Organization
Arcus Biosciences 107
Beckman Coulter 105
BioLegend 102
Cellular Technology Limited 110
FOCIS 112
Immudex 113
iRepertoire, Inc. 101
JPT Peptide Technologies 121
Merck 106
Myriad RBM 111
Nanostring Technologies 123
Science Immunology 104

Room Locations
Lower Level
Stevens Salon A (1-5)
Stevens Salon C (1-4)

Lobby Level
Hotel Lobby
Hotel Restaurants
Kitty O’Sheas

2nd Floor
Boulevard AB
Grand Ballroom
Grand Foyer
Normandie Lounge

3rd Floor
PDR 2-6
Williford A
Williford B
Williford C
FOCIS 2017
EUROPEAN ADVANCED COURSE IN BASIC AND CLINICAL IMMUNOLOGY
OCTOBER 16 – 18, 2017, PRAGUE, CZECH REPUBLIC

MORE DETAILS WILL BE PUBLISHED SOON ON WWW.FOCISNET.ORG
(SECTION EDUCATION/EUROPEAN ADVANCED COURSE)
International Archives of Allergy and Immunology

welcomes your contribution...

In addition to original papers it features short communications, reviews, minireviews, commentaries and opinions. Supported by online submission and peer-review systems, a team of internationally renowned and committed editors guarantees a fair review process, high scientific quality and fast dissemination of significant and novel work.

Benefits for Authors
- Cost-effective publishing (no submission fee and no page charges for papers of 5 or fewer printed pages)
- Free online color figures
- Rapid and fair peer-review process
- Full listing in all relevant bibliographic databases (PubMed/MEDLINE, Web of Science, Biological Abstracts, Chemical Abstracts, etc.)
- Impact Factor: 2.677
- Author’s choice for open access publishing

The international forum for high-quality, innovative research in allergy and immunology

Editor-in-Chief
Rudolf Valenta, Vienna
Barbara Bohle, Vienna

Associate Editors
F. Annunziato, Florence
K. Blaser, Davos
J. Bousquet, Montpellier
A.W. Burks, Chapel Hill, N.C.
D. Dombrowicz, Lille
M. Ebisawa, Kanagawa
H. Garn, Marburg
P. Gevaert, Ghent
J. Gutermuth, Brussels
T. Jakob, Giessen
V. Niederberger-Leppin, Vienna
M. Ollert, Esch-sur-Alzette
E. Padovan, Basel
R. Pawankar, Tokyo
W.F. Pickl, Vienna
A. Radbruch, Berlin
H. Saito, Tokyo
C.B. Schmidt-Weber, Munich
T. Schwarz, Kiel
W. Thomas, Perth, W.A.
M. Triggiani, Naples
R. van Ree, Amsterdam

International Archives of Allergy and Immunology
2017: Volumes 172, 173, 174
4 issues per volume
Language: English
ISSN 1018–2438 / e-ISSN 1423–0097

Beneﬁts for Authors
- Cost-eff ective publishing
- Free online color ﬁgures
- Rapid and fair peer-review process

Full listing in all relevant bibliographic databases (PubMed/MEDLINE, Web of Science, Biological Abstracts, Chemical Abstracts, etc.)
- Impact Factor: 2.677
- Author’s choice for open access publishing

Find out more: www.karger.com/iaa

The Journal of Rheumatology
VOLUME 38
jrheum.org
PRINTED IN CANADA – ISSN 0315-162X

August 2016

Where you get it
THE JOURNAL

What you get
- Current
- Clinical
- Definitive

To subscribe: visit jrheum.org online or send in your completed coupon below

Rates for 2017 calendar year
USA/INTERNATIONAL

INDIVIDUALS:
Print + Online $350 US
Online Only $285 US

INSTITUTIONAL:
- Multisite* On request
- Multisite (IP ranges) $1025 US
- Basic-Plus (IP ranges) $750 US
- Basic (up to 4 users) $550 US
- TRAINEES* $215 US
- AIRMAIL (ADD) $120

For terms of access visit jrheum.org
*Supervisor certification required below.

NAME OF SUPERVISOR: ____________________________
SUPERVISOR SIGNATURE: ____________________________
SUPERVISOR TELEPHONE: ____________________________

Mail completed form to: The Journal of Rheumatology
365 Bloor Street East, Suite 901
Toronto, Ontario Canada M4W 3L4
Phone: (416) 967-9100
Fax: (416) 967-7506
E-mail: subscriptions@jrheum.com

Please enter my 2017 subscription to The Journal of Rheumatology

Name (please print) ____________________________

Address

City ____________________________ State/Province ______

Country ____________________________ Zip/Postal Code ______

Contact E-mail ____________________________

Amount Enclosed $_________ Bill Me ______

Telephone Number ____________________________ Fax Number ____________________________

VISA/MasterCard Number ____________________________ Expiration Date ______

Signature ____________________________ CVV ______

All subscriptions are for the calendar year. Renewals for print subscriptions received after May 31, 2017 will be charged an additional $10 per back issue. Back issues: 2 years including current year are available if in stock. Single copies are available at $30 each. Claims: US 2 months, elsewhere 4 months from issue date, e.g., March 1 and May 1, respectively, for the January Issue. PRIVACY POLICY: For details of our privacy policy, visit our website at www.jrheum.org.
It begins with a promise
to discover medicines that make life better.

Since 1876, we have worked tirelessly to develop and deliver trusted medicines that meet real needs, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

To find out more about our promise, visit www.lilly.com/about.